AAN 2026 | Significant improvement in wakefulness with E2086 for narcolepsy: findings from a Phase I trial

So, Eisai’s study evaluated E2086, which is a new orexin-2 receptor agonist. This is for treatment of narcolepsy. Specifically, this study involved type 1 narcolepsy, that is patients with narcolepsy and cataplexy with orexin deficiency. So the study was a five-way crossover study involving a single dose of either modafinil, placebo, or three doses of E2086. So this study looked at various doses and compared these doses with placebo or modafinil, which is a standard treatment for narcolepsy. And what was found was that all of these doses separated from placebo in terms of promoting wakefulness. And this was identified with a maintenance of wakefulness test, which is a standardized method of objectively determining the degree of excessive daytime sleepiness. And furthermore, the two higher doses separated from modafinil in terms of subjective sleepiness. This is evaluated by the Karolinska sleepiness scale, which is also a well-recognized method of evaluating subjective daytime sleepiness. So this is an important study in that it demonstrated that these several doses of this new orexin agonist substantially separated both from placebo and from existing therapies for treatment of narcolepsy type 1. And this is an emerging therapy that’s going to be very effective, not only for people with type 1 narcolepsy, but also eventually for type 2 narcolepsy as well.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.